Targeted Therapies in Early Stage NSCLC: Hype or Hope?

Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an incidence that increases yearly across the world. The introduction in clinical practice of several new and more effective molecules has led to a consistent improvement in survival and quality of life in locally advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedlaender, Alex, Addeo, Alfredo, Russo, Alessandro, Gregorc, Vanesa, Cortinovis, Diego, Rolfo, Christian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504271/
https://www.ncbi.nlm.nih.gov/pubmed/32878298
http://dx.doi.org/10.3390/ijms21176329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504271/
https://www.ncbi.nlm.nih.gov/pubmed/32878298
http://dx.doi.org/10.3390/ijms21176329

Ejemplares similares